Literature DB >> 16778767

The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization.

Angélique Levoye1, Julie Dam, Mohammed A Ayoub, Jean-Luc Guillaume, Cyril Couturier, Philippe Delagrange, Ralf Jockers.   

Abstract

One-third of the approximately 400 nonodorant G protein-coupled receptors (GPCRs) are still orphans. Although a considerable number of these receptors are likely to transduce cellular signals in response to ligands that remain to be identified, they may also have ligand-independent functions. Several members of the GPCR family have been shown to modulate the function of other receptors through heterodimerization. We show that GPR50, an orphan GPCR, heterodimerizes constitutively and specifically with MT(1) and MT(2) melatonin receptors, using biochemical and biophysical approaches in intact cells. Whereas the association between GPR50 and MT(2) did not modify MT(2) function, GPR50 abolished high-affinity agonist binding and G protein coupling to the MT(1) protomer engaged in the heterodimer. Deletion of the large C-terminal tail of GPR50 suppressed the inhibitory effect of GPR50 on MT(1) without affecting heterodimerization, indicating that this domain regulates the interaction of regulatory proteins to MT(1). Pairing orphan GPCRs to potential heterodimerization partners might be of clinical importance and may become a general strategy to better understand the function of orphan GPCRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778767      PMCID: PMC1500982          DOI: 10.1038/sj.emboj.7601193

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  48 in total

Review 1.  Oligomerization of G-protein-coupled transmitter receptors.

Authors:  M Bouvier
Journal:  Nat Rev Neurosci       Date:  2001-04       Impact factor: 34.870

2.  Localization of the melatonin-related receptor in the rodent brain and peripheral tissues.

Authors:  J E Drew; P Barrett; J G Mercer; K M Moar; E Canet; P Delagrange; P J Morgan
Journal:  J Neuroendocrinol       Date:  2001-05       Impact factor: 3.627

3.  Chimeric melatonin mt1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor.

Authors:  S Conway; J E Drew; E S Mowat; P Barrett; P Delagrange; P J Morgan
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

4.  The angiotensin II AT2 receptor is an AT1 receptor antagonist.

Authors:  S AbdAlla; H Lother; A M Abdel-tawab; U Quitterer
Journal:  J Biol Chem       Date:  2001-08-15       Impact factor: 5.157

5.  Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease.

Authors:  E Savaskan; G Olivieri; L Brydon; R Jockers; K Kräuchi; A Wirz-Justice; F Müller-Spahn
Journal:  Neurosci Lett       Date:  2001-07-27       Impact factor: 3.046

6.  Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins.

Authors:  L Brydon; F Roka; L Petit; P de Coppet; M Tissot; P Barrett; P J Morgan; C Nanoff; A D Strosberg; R Jockers
Journal:  Mol Endocrinol       Date:  1999-12

7.  Sequence variants in the melatonin-related receptor gene (GPR50) associate with circulating triglyceride and HDL levels.

Authors:  Sumit Bhattacharyya; Jian'an Luan; Benjamin Challis; Julia Keogh; Carl Montague; John Brennand; John Morten; Sarah Lowenbeim; Suzanne Jenkins; I Sadaf Farooqi; Nicholas J Wareham; Stephen O'Rahilly
Journal:  J Lipid Res       Date:  2006-01-25       Impact factor: 5.922

8.  Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries.

Authors:  Q Yang; E Scalbert; P Delagrange; P M Vanhoutte; S T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-01       Impact factor: 4.733

9.  Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer.

Authors:  Mohammed A Ayoub; Cyril Couturier; Estelle Lucas-Meunier; Stephane Angers; Philippe Fossier; Michel Bouvier; Ralf Jockers
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

10.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation.

Authors:  B A Jordan; N Trapaidze; I Gomes; R Nivarthi; L A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  110 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 6.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

Review 7.  Identifying ligands at orphan GPCRs: current status using structure-based approaches.

Authors:  Tony Ngo; Irina Kufareva; James Lj Coleman; Robert M Graham; Ruben Abagyan; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

Review 8.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

9.  Targeting pancreatic progenitor cells in human embryonic stem cell differentiation for the identification of novel cell surface markers.

Authors:  Bettina Fishman; Hanna Segev; Oded Kopper; Jonathan Nissenbaum; Margarita Schulman; Nissim Benvenisty; Joseph Itskovitz-Eldor; Danny Kitsberg
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 10.  Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers.

Authors:  Angélique Levoye; Julie Dam; Mohammed A Ayoub; Jean-Luc Guillaume; Ralf Jockers
Journal:  EMBO Rep       Date:  2006-11       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.